News
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.43% to 5,631.28 and the Dow Jones Industrial Average DJIA rising 0.70% to 41,113.97.
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results was that the company missed Wall Street's revenue and earnings estimates.
Zacks Investment Research on MSN19h
VRTX Stock Down as Q1 Sales of New Drugs Miss ExpectationsVertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...
Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...
VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...
Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors ...
One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...
Zacks Investment Research on MSN1d
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View TightenedVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback